Commercialising
the Inhibitor
SCENARIOS
MISCELLANEOUS
Cover here, which law governs the contract; how changes can be
made; whether the contract is assignable.
SIGNATURES
Make sure it is signed by people AUTHORISED to sign and bind each
party.
During negotiations, IPP has suggested that, due to Prof. Table's input, it
also has rights in the treatment. If this is correct, it may mean that Lakeland
would need a licence from IPP if it wished to use the IP.
Working on the basis that Lakeland does require a licence from IPP,
what issues will Lakeland need to consider in negotiating the terms
of the licence back?
You may wish to consider the fact that Lakeland is keen to use the
research and development of the treatment for non-commercial
purposes (e.g. in teaching materials) rather than just in relation
to research on breast cancer treatment.
Brian Hodgson continues to research in the area of aromatose inhibitors
after the licence has been signed with IPP and has created new
improvements. He has written a detailed paper about his work which
he wants to submit to a scientific journal. What should Brian be thinking
about in relation to:
n IP
protection
n the
n his
relationship with IPP
approach to a publisher, bearing in mind his relative inexperience.
A look back at the Academic Materials and Publishing Guide may help
you here.
32
